Condition: Heart Defects, Congenital · Pulmonary Arterial Hypertension · Genetic Testing · Sponsor: Universitaire Ziekenhuizen KU Leuven
Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is associated with considerable morbidity and even mortality. Next to environmental risk factors, the investigators believe that there is an important role of genetic predisposition to develop PAH in CHD. There often is a discrepancy between the severity of PAH and the CHD, where it is useful to screen for PAH gene mutations. The investigators hypothesize that the genotype is partly responsible for the phenotypic variability in patients with congenital shunt lesions, where some develop PAH and others do not. If a genetic predisposition for PAH in CHD could be identified, then genetic screening could be a useful additional tool for early detection of patients at risk of pulmonary vascular disease and PAH development, with new opportunities for prevention or early treatment.
This description comes directly from the study's public registry record.
Werner Budts, MD, PhD · +32 16 344369 · werner.budts@uzleuven.be
Charlien Gabriels, MD · +32 16 341486 · charlien.gabriels@uzleuven.be
Always discuss trial participation with your own doctor first.
| University Hospitals Leuven | Leuven, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02691689